Cara Therapeutics Stock Net Income
| 69C Stock | EUR 4.84 0.00 0.00% |
Cara Therapeutics fundamentals help investors to digest information that contributes to Cara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cara Stock. The fundamental analysis module provides a way to measure Cara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cara Therapeutics stock.
Cara |
Cara Therapeutics Company Net Income Analysis
Cara Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cara Therapeutics Net Income | (88.44 M) |
Most of Cara Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Cara Therapeutics reported net income of (88.44 Million). This is 125.91% lower than that of the Healthcare sector and 226.26% lower than that of the Biotechnology industry. The net income for all Germany stocks is 115.49% higher than that of the company.
Cara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cara Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cara Therapeutics could also be used in its relative valuation, which is a method of valuing Cara Therapeutics by comparing valuation metrics of similar companies.Cara Therapeutics is currently under evaluation in net income category among its peers.
Cara Fundamentals
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X | |||
| Revenue | 23.03 M | |||
| Gross Profit | (59.67 M) | |||
| EBITDA | (88.83 M) | |||
| Net Income | (88.44 M) | |||
| Cash And Equivalents | 134.45 M | |||
| Cash Per Share | 3.38 X | |||
| Total Debt | 4.99 M | |||
| Debt To Equity | 4.30 % | |||
| Current Ratio | 3.40 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (60.09 M) | |||
| Earnings Per Share | (1.50) X | |||
| Target Price | 26.33 | |||
| Number Of Employees | 84 | |||
| Beta | 0.96 | |||
| Market Capitalization | 508.24 M | |||
| Total Asset | 247.06 M | |||
| Z Score | 60.6 | |||
| Net Asset | 247.06 M |
About Cara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.